HALO
Halozyme Therapeutics
October 14, 2026 · market open
- Rarity
- 2.38
- Peak move
- +8.47%
- Float cap
- $12.8B
Halozyme Therapeutics is a biopharmaceutical drug-delivery company based in San Diego that licenses its Enhanze technology, built on the proprietary enzyme rHuPH20, to large pharmaceutical partners including Roche, Johnson & Johnson and argenx. Enhanze converts intravenously administered biologics into subcutaneous injections and supports extended dosing intervals, generating royalties on partner product sales. The company also sells its own products, Hylenex and Xyosted, and offers autoinjector and hyperconcentration formulation technologies.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingTD Cowen raised its price target on Halozyme Therapeutics to $130 from $105 and kept a Buy rating on October 13, 2026, adjusting life-science-tools targets as part of a Q3 preview.
buybackHalozyme Therapeutics' board approved a new $500 million share repurchase program on October 13, 2026, authorizing repurchases of its common stock in the open market or in privately negotiated transactions.
analyst_ratingH.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics and raised the 12-month price target to $130 from $115 on October 13, 2026, citing the FDA approval of Roche's ENHANZE-enabled Tecentriq Hybreza for Stage 3 dMMR colon cancer and the resulting royalty opportunity.
regulatory_approvalThe FDA on October 8, 2026 approved Genentech/Roche's Tecentriq and ENHANZE-enabled subcutaneous Tecentriq Hybreza with chemotherapy as adjuvant treatment for stage III dMMR colon cancer, the first approved adjuvant immunotherapy regimen for that population.
patent_eventThe specialized Dutch patent court of The Hague granted Halozyme an injunction finding its EP 297 622 patent valid and infringed, barring MSD from making, selling, importing or stockpiling subcutaneous Keytruda SC in eight European markets including Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.